Day: June 28, 2022

ABB Ty-Rap® TyGenic™ ABB’s new Ty-Rap® TyGenic™ cable ties are the industry’s first two-piece cable tie that is both antimicrobial* and detectableABB Ty-Rap® TyGenic™ ABB Ty-Rap® TyGenic™ helps protect against costly contamination and waste in food and beverage and pharmaceutical processing, healthcare and hygiene-critical locationsCary, NC, June 28, 2022 (GLOBE NEWSWIRE) —ABB’s new Ty-Rap® TyGenic™ cable ties are the industry’s first two-piece cable tie that is both antimicrobial* and detectableOver 99 percent effective against a broad spectrum of microorganisms and detectable by x-ray, visual and metal detection systemsHelps protect against costly contamination and waste in food and beverage and pharmaceutical processing, healthcare and hygiene-critical locationsThe cost of contamination can add up, averaging...

De Novo marketing authorization planned for early 2025 remains unchanged TORONTO, June 28, 2022 (GLOBE NEWSWIRE) — Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that multiple disruptions have resulted in an updated Investigational Device Exemption (IDE) submission timeline for the Enos™ robotic single access surgery system. The company now expects the IDE submission to occur mid-year 2023 instead of the first quarter of 2023. Pending successful regulatory review and upon receipt of marketing authorization, the expected U.S. product launch for the Enos system remains on schedule for early 2025. “We have been fortunate to have avoided and mitigated against many...

DODGEVILLE, Wis., June 28, 2022 (GLOBE NEWSWIRE) — Lands’ End, Inc. (NASDAQ: LE) announced today that its Board of Directors has authorized the repurchase of up to $50 million of the Company’s common stock through February 2, 2024, the conclusion of its fiscal year 2023. Under the program, the Company may purchase its shares from time to time in the open market, in privately negotiated transactions, or by other means in accordance with federal securities laws. Simultaneously, the Company continues to explore debt refinancing options as part of its ongoing commitment to drive stockholder value. Jim Gooch, President and Chief Financial Officer of Lands’ End, said, “This share repurchase authorization exemplifies both the Board’s and management’s confidence in the strength of our business model and our long-term growth prospects....

RESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Jacks Lee to its Board of Directors. For more than 30 years, Mr. Lee has developed extensive experience in manufacturing and supply chain management in the life sciences industry. Mr. Lee currently serves as Senior Vice President – Manufacturing & Supply of Merck & Co., Inc., a global premier research-intensive biopharmaceutical health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. “G1’s Board of Directors comprises executives with life science careers defined by sound strategic execution, unquestionable integrity, and strong business leadership;...

FREMONT, Calif., June 28, 2022 (GLOBE NEWSWIRE) — Enovix Corporation (“Enovix”) (Nasdaq: ENVX), the leader in the design and manufacture of next generation 3D Silicon™ Lithium-ion batteries, today announced it has broadened its leadership team responsible for bringing its cell technology to the Electric Vehicle (EV) market. Enovix Mobility will be led by James Wilcox, PhD. Dr. Wilcox joined Enovix in 2008 as part of the core engineering team that developed the company’s proprietary stacked cell architecture. Enovix also hired Spencer Gore as Head of EV products. Dr. Wilcox and Gore will join Pat Donnelly, Vice President, Strategic Business Development, on the Enovix Mobility leadership team, and together, they will execute the company’s EV product and business strategy.  “As we continue to execute our plans to bring Enovix technology...

WEST CHESTER, Pa., June 28, 2022 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the Company held a Type A meeting with the U.S. Food and Drug Administration (FDA) on June 27, 2022 regarding the path forward for the resubmission and potential approval of the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum). “We are pleased with our communications with the FDA leading up to and during yesterday’s Type A meeting,” said Ted White, Verrica’s President and Chief Executive Officer. “In particular, we are encouraged by the FDA’s willingness to work collaboratively with us on the amount of stability data required from an alternative contract...